Drugs / Aleeto
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06765733 | May 2025 → Sep 2026 overdue | multiple system atrophy, parkinsonian type | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06181526 | Dec 2023 → Oct 2024 | amyotrophic lateral sclerosis | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06759753 | Mar → Nov 2025 overdue | ischemic stroke | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aleeto | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06181526 ↗ |
| Modality | Protein / enzyme biologic | “Aleeto" derived from cellular exosomes, is a group of specific microenvironment protein polymers secreted by stem cells under stressed conditions” NCT06181526 ↗ |
| Route | Intrathecal | “intrathecal administration of Aleeto” NCT06181526 ↗ |